

Index

Abbreviations used in subentries:

- ASD – atrial septal defect
- CHD – congenital heart disease
- PPCM – peripartum cardiomyopathy
- SVT – supraventricular tachycardia
- TGA – transposition of the great arteries
- VSD – ventricular septal defect

-
- ablation techniques 79
 - absent end-diastolic flow (AED)
 - 101–102
 - ACTA2 gene mutation 118
 - activated partial thromboplastin time (APTT) 107–108, 112
 - acute coronary syndrome 3, 175–177
 - see also* myocardial infarction
 - acyanotic heart disease 98–99
 - adenosine 186
 - adolescents, counseling 6, 43
 - adverse incident reporting, cardiac drugs 54
 - air embolism 214
 - aldosterone antagonists 55
 - alkalosis, maternal 103
 - amiloride 55
 - amiodarone 57, 185, 188
 - amniocentesis 89
 - analgesia
 - in puerperium 224–225
 - regional 211–213, 224
 - anemia, physiological, in pregnancy 21
 - anesthesia 211–214
 - arrhythmias (maternal) 187–188, 213
 - general 211, 213–214
 - advantages 213
 - cesarean section 211, 213
 - disadvantages 213–214
 - hemodynamics 25
 - hypertrophic cardiomyopathy 170
 - maternal CHD surgery, effect on fetus 103
 - pulmonary hypertension 156–157, 213
 - regional 211–212
 - advantages 212
 - contraindications 212
 - pulmonary hypertension 157
 - safe use, technical aspects 212
 - aneuploidies, screening 100
 - aneurysm 116, 121
 - angiography 174
 - angiotensin-converting enzyme (ACE) inhibitors 53, 56
 - breastfeeding 53, 56
 - postpartum, PPCM 165
 - in pregnancy, risk to fetus 32, 53, 56, 176, 202
 - first trimester 56
 - second/third trimesters 56
 - angiotensin I/II 19, 21
 - angiotensin II inhibitors 53, 56–57, 176
 - antenatal care
 - admission to hospital 34
 - cardiologist's perspective 36–42
 - consensus statements 36
 - fetal surveillance 33–34, 47
 - frequency of visits 34, 46
 - initial patient assessment 43–44, 47
 - integrated pathway and records 33, 46–47
 - location 31, 46
 - medication assessment 47, 54
 - multidisciplinary team 33, 38–39, 46
 - obstetrician's perspective *see* obstetrician
 - organization/delivery 36, 38–39, 45–47
 - hierarchy 40, 41, 45–46
 - high-risk group (WHO III/II-III) 46
 - limitations/solutions 42
 - low-risk group (WHO I/II) 45
 - pathways 40, 204
 - recommendations 40–41
 - UCLH experience 42
 - planning 32–33
 - risk assessment *see* risk assessment
 - routine checks 33
 - specialist CHD unit 39, 41
 - specialist services 39, 41, 46
 - antiarrhythmic drugs 57–58, 177, 182, 185–186
 - class(es) IA, IB, and IC 57, 186
 - class 2 57, 58–59, 186
 - class 3 57–58, 186
 - class 4 58, 186
 - effects of fetus 182
 - transplacental 91
 - antibiotic(s)
 - endocarditis treatment 191, 196, 197
 - prophylaxis 191
 - cesarean section 194
 - dental treatment 194
 - endocarditis 75, 119, 191, 193–194
 - guidelines 194
 - low-risk cardiac lesions 31
 - perineal injury 194
 - right heart lesions 132
 - vaginal delivery 193–194, 196
 - safety in pregnancy 197
 - anticoagulation
 - Fontan-type operations 139, 140
 - general anesthesia and 213
 - see also* prosthetic heart valves
 - before pregnancy 4
 - in pregnancy 47, 59–60, 138
 - in puerperium 224
 - anti-hypertensives 55–57
 - anti-Xa levels 111, 112
 - aorta
 - changes in pregnancy 76, 236
 - dimensions, echocardiography 50
 - “fragile” 25
 - normal function in pregnancy 115

Index

- aortic aneurysm 116
 aortic dissection 16, 50, 75–76
 ACTA2 gene mutation 118
 bicuspid aortic valve 232
 causes 115–116
 distal (type B) 75, 117
 emergency surgery 76
 Marfan syndrome *see* Marfan syndrome
 maternal mortality 75, 115
 prophylactic aortic root replacement 76
 puerperium 221
 risks, preconception counseling 3
 symptoms 119
 treatment during pregnancy 119
 Turner syndrome 122
 aortic regurgitation 49, 74–75
 aortic root
 dilatation 37, 50, 115, 231–232, 236, 237
 Marfan syndrome 115, 117, 231–232, 236
 measurement 50, 118
 in puerperium 223
 replacement 76, 117, 119
 aortic stenosis (AS) 49, 73–74, 127–130
 antenatal monitoring 129
 causes 125, 127–128
 complications/sequelae of pregnancy 128
 congenital, effect of pregnancy on 231
 critical 129
 decompensation, signs/symptoms 129
 fetal, transcatheter intervention 92
 isolated, prepregnancy assessment 128–129
 labor and delivery 130
 long-term outcome after pregnancy 231
 severe 73, 128–129, 130
 severity, classification 128
 therapeutic interventions 73–74, 128–129
 balloon valvotomy 74, 129
 balloon valvuloplasty 74
 medical 73, 129
 surgical 73–74, 129–130
 aortic valve
 balloon valvotomy 74, 129
 bicuspid 76, 122, 125, 236, 237
 long-term outcome 232, 236
 disease, morbidity in puerperium 222–223
 replacement 73, 74, 128–130, 231
 aortocaval compression 212, 215, 219
 aortocoronary bypass surgery 68, 76, 77–78
 aortopathies 115–123
 causes 115–116
 delivery issues 119–120
 long-term outcome 231–232, 236–237
 Marfan syndrome *see* Marfan syndrome
 monitoring during pregnancy 118–119
 practical clinical points 115
 pregnancy counseling 237
 treatment during pregnancy 119
 see also individual aortopathies
 arrhythmias, fetal, in CHD 91
 assessment 91
 management 91–92
 arrhythmias, maternal 180–188
 anesthetic management 187–188
 breastfeeding 188
 in CHD 181, 182, 186–187
 contraception 187
 effect on mother/fetus 181–182, 187
 fetal cardiac screening in 187
 in heart disease during pregnancy 3, 181–182
 mechanisms 181–182
 structural heart disease 3, 181
 heart transplant recipient 201
 incidence in pregnancy 180–181, 182
 management in pregnancy 79, 182
 catheter ablation 79, 184
 DC cardioversion 58, 184
 implantable cardioverter-defibrillator 79
 pacemakers 79, 185
 maternal mortality 187
 maternal surveillance during pregnancy 187
 multidisciplinary team approach 188
 postpartum management 188
 practical practice points 180
 in puerperium 221
 risks, preconception counseling 3, 187
 types in pregnancy 180
 without underlying cardiac disease 180–181
 arrhythmogenic right ventricular cardiomyopathy (ARVC) 160, 170
 arterial line, monitoring 214
 arterial thrombosis, contraception risk 11
 aspirin 60, 77
 see also low-dose aspirin
 assisted conception 4, 70
 atosiban 62
 atrial arrhythmias, in ASD 134
 atrial fibrillation 126, 183, 184
 atrial flutter 183–184
 atrial natriuretic peptide (ANP) 21, 26
 atrial septal defect (ASD) 78, 99, 133–134, 135
 forms/types and anatomy 133
 indications for closure 133
 maternal complications 134
 pregnancy toleration 133–134
 atrial switch operation 137, 187, 235
 atrioventricular block (AVB) 180
 complete 181, 182, 185
 second degree 185
 atrioventricular nodal re-entry tachycardia (AVNRT) 183
 atrioventricular reciprocating tachycardia (AVRT) 183
 atrioventricular valve regurgitation 235
 autoantibodies 86, 92, 163, 164
 autonomy of woman 2, 29
 autotransfusion of blood 210, 219
 bacteremia 191–193, 221
 balloon aortic valvotomy 74, 129
 barrier contraception 14
 Bernoulli equation 146
 beta-blockers 53, 58–59, 185
 cardiomyopathies 162, 169
 fetal growth restriction 59
 Marfan syndrome 115, 118
 neonatal risks 59
 paroxysmal SVT 183
 PPCM 165
 bicuspid aortic valve disease (BAVD) 122
 blood loss, at delivery 25, 187, 210, 213–214, 220
 see also postpartum hemorrhage
 blood pressure 67
 measurement 30, 121
 normal pregnancy 19, 21, 30, 200
 peridelivery 25
 blood volume
 normal pregnancy 19–21, 148, 174
 peridelivery 25, 148, 210
 puerperium 219–220
 pulmonary hypertension, postpartum 148
 structural heart disease 181
 bosentan 13, 15, 58, 152
 bradyarrhythmias 181, 185
 bradycardia, fetal 67, 68, 92
 brain-sparing effect 102
 breastfeeding
 drugs and 54, 218
 ACE inhibitors 53, 56
 amiodarone 57

- angiotensin II inhibitors 56–57
 calcium channel blockers 58
 furosemide 55
 heparin 60
 hydralazine 56
 sotalol 58
 spironolactone 55
 thiazide diuretics 55
 warfarin 60
- heart-lung transplant recipients 206
 maternal arrhythmias 188
 peripartum cardiomyopathy 165
 bromocriptine 164, 165, 222
 bundle branch block (BBB) 181
- calcineurin inhibitors 203, 205
 calcium channel blockers 58, 176, 185
 carboprost 61, 211
 cardiac afterload, reduction in
 pregnancy 19, 21, 218
 cardiac arrest 215
 cardiac catheterization 51, 175
 cardiac disease (maternal)
 assessment (antenatal) 43–44
 burden increase/frequency
 29, 36, 37
 classification 7–8, 43, 97
 cardiac function (NYHA)
 32, 44, 97
 maternal mortality/morbidity 8,
 96, 208
 risk (WHO) 38
 diagnosis 30–31
 drugs used in pregnancy
 affecting 60–62
 impact of pregnancy on *see*
 long-term outcome
 predictors of adverse outcome 97
 pregnancy risk 1, 7–8
 risk assessment *see* risk assessment
 significance in peripartum period
 208–209
 spectrum 37–38
 cardiac drugs 53–62
 adverse incident reporting 54
 balancing risks and
 assessment 47, 54
 breastfeeding *see* breastfeeding
 effect on fetus 53
 pharmacokinetics 53
 potential adverse effects 53–54
 practical practice points 53
 prescribing before pregnancy 54
 used in puerperium 224
see also specific drugs
 cardiac history 30
 cardiac investigations, antenatal
 30–31
 cardiac monitoring
 postpartum 47
- in pregnancy 43–51
 care organization *see*
 antenatal care
 initial assessment 43–44
 practical practice points 43
see also specific modalities
 in puerperium 224
 cardiac MRI 31, 51, 70
 aortopathies 118–119
 congenitally corrected TGA 136
 dilated cardiomyopathy 161
 fetal CHD diagnosis 93
 left to right shunting in ASD
 133, 134
 pulmonary atresia with VSD 140
 right heart lesions 131
 transposition of great arteries 137
 cardiac murmurs 30
 cardiac output (CO)
 normal pregnancy 20, 21, 22, 30,
 148, 174, 200
 peridelivery 25, 30, 148, 174, 200,
 209, 218–219
 non-invasive monitoring 214–215
 second stage of labor 209, 219
 third stage of labor 209
 postdelivery 219
 puerperium, monitoring 224
 cardiac preload 21, 22
 cardiac pressures, estimation 50
 cardiac shunting of blood, alteration
 220–221
 cardiac surgical interventions 29, 39,
 65–79, 177
 anesthesia effect on fetus 103
 cardiopulmonary bypass *see*
 cardiopulmonary bypass
 in CHD 102–103
 developing countries 66
 in endocarditis 75, 197
 fetal monitoring during 103
 immediate delivery 103
 indications, risk factors 65, 102
 practical practice points 65
 prevalence 65
 valvar heart disease 71–75
see also specific conditions and
procedures
 cardiac thrombosis/
 thromboembolism 12
 cardiac transplant *see* heart
 transplantation
 cardiac tumors, removal 79
 cardiogenic shock 221
 cardiologists, perspective on antenatal
 care 36–42
 cardiomyopathies 160–170
 inherited 37, 161, 169, 230
 long-term outcome after
 pregnancy 230
- morbidity in puerperium 222
 mortality, timing 222
 practical practice points 160
 pregnancy-associated 162, 230
 restrictive 160, 170
see also other specific
cardiomyopathies
 cardioplegia, chemical 66, 67
 cardiopulmonary bypass 65, 103,
 129–130
 components 66
 fetal and maternal risks 66–68, 103,
 119, 129
 mortality rates 66, 102, 129
 high-pressure, high-flow 103,
 119, 177
 key points 68–69
 modifications in pregnancy 67, 119,
 129–130, 177
 normothermic 103
 uterine contractions 67
 cardiovascular changes
 in normal pregnancy 19–26, 67
 148
 anatomical 22–23, 25, 30
 functional 23–25
 hemodynamic *see* hemodynamic
 changes
 practical practice points 19
 peridelivery/labor 25–26, 210–211
 postpartum 26
 cardiovascular events, maternal,
 predictors 44, 45
 cardioversion, electrical 58, 184
 cardioverter-defibrillator 79, 167, 184
 care networks 51
 CARPREG scoring system 44
 catecholamines 201
 catheter ablation, arrhythmia 70, 184
 catheter interventions 65–79
 percutaneous *see* percutaneous
 coronary intervention (PCI)
 CEMACE recommendations 37
 central venous catheter 214
 cerebral vasodilatation 102
 cesarean section 210
 anesthesia 211, 212, 213
 antibiotic prophylaxis 194
 bacteremia after 221
 blood loss 213–214
 indications 210
 during maternal cardiac
 surgery 103
 pulmonary hypertension 156
 risks and maternal mortality
 210, 212
 sterilization at time of 11
 vaginal delivery *vs* 61
 chest pain, myocardial infarction 175
 chest X-ray 126, 135, 154

Index

- chronic thromboembolic pulmonary hypertension (CTEPH) 145
- classification, cardiac disease *see* cardiac disease (maternal)
- clopidogrel 60, 77, 176
- coarctation of aorta 76, 78–79, 120–122, 237
 associated lesions/sequelae 120, 121–122
- diagnosis 120
- hypertension 120–121
- management options 120
- native, in pregnancy 120
- recoarctation 121
- recurrence risk (in fetus) 122
- repaired 120–122
- transcatheter stenting 79
- colloid osmotic pressure (COP) 218, 220
- combined hormonal contraception (CHC) 11–12, 204
 risk classification 10, 11–12
- computed tomography (CT) 51, 119
- Confidential Enquiries into Maternal Deaths in the UK 125, 193, 195
- congenital heart disease (CHD), in fetus/child
 antenatal diagnosis 33–34, 84–93
 counseling after 89
 detection rate 100
 early 33–34, 92, 100
 effect on outcome 84–85
 equipment required 88–89
 fetal medicine assessment 89
 first trimester screening 92, 100
 guidelines 85–86, 88
 imaging technique advances 93
 level 1 screening 85
 level 2 screening 85–86
 nuchal translucency *see* nuchal translucency
 practical practice points 84
 screening in local obstetric units 85–86
 suspected screening abnormality 88
 in tertiary center 86
 timing of screening 84, 86
 ultrasound *see* echocardiography
- complications 96
- delivery mode 91
- delivery timing/site 90–91
- extracardiac anomalies with 88
- indications for referral to fetal cardiology 86–88, 100
- interventions (fetal) 91, 92
- intrauterine death 90
- new challenges/future prospects 92–93
- ongoing assessment, fetal well-being 90, 96, 101–102
- outcome prediction 93, 96
- prevalence/burden/risk 4–5, 37, 44, 84, 96
- progression during pregnancy 90
- recurrence risk 4, 44, 86, 99, 100
- risk factors 85, 87–88
- termination of pregnancy 90, 100
- congenital heart disease (CHD),
 maternal 96–103, 234
- arrhythmias in 181, 182
- cardiovascular events, predictors 44, 45, 96–97
- complications 98, 131–132
- cyanotic conditions, fetal outcome 98
- cyanotic vs acyanotic disease 98–99
- delivery 216
- endocarditis 192, 193
- fetal CHD risk in 4, 44, 86, 99, 100
- fetal monitoring during surgery 103
- fetal surveillance 99–101
- improved survival 234
- indices 97–98
- long-term complications of pregnancy 227
- outcome predictors 96–97, 131–132, 227
- peripartum period, risks 208–209
- practical practice points 96
- preconception counseling 1, 3, 4–5
- prevalence/burden 29, 37, 78, 96, 131
- pulmonary hypertension in 147
- pulmonary vascular remodeling 50
- risk factors 85, 86–87, 96–97
- surgery in pregnancy 78–79, 102–103
 anesthesia effect on fetus 103
see also specific conditions
- congenitally corrected transposition of the great arteries (ccTGA) 136–137, 187
- connective tissue disorders 236–237
- consensus statements ix, x, 36, 67
 general overarching views 70
 meeting participants 70, 165
 pregnancy in pulmonary hypertension 148, 152
- consent, contraception 6
- continuity equation 49
- contraception 4, 6–16, 73
 classification 6, 7, 10
 consent 6
 counseling 6–7
 emergency *see* emergency contraception
 heart-lung transplant recipients 204
- importance, specific diseases 15–16
- information on, preconception counseling 3, 6–7
- Marfan syndrome 16
- maternal arrhythmias 187
- practical practice points 6
- pulmonary hypertension 15–16, 152
- contraceptive agents 8
 choice, factors involved 8
 classification (UKMEC) 10
 efficacy 8–11 *see also specific contraceptives*
- contrast agents, fetal and maternal risks 69–71
- COP-PCWP gradient 218, 220
- copper intrauterine device (Cu-IUD) 10, 14, 152
 emergency contraception 14
 heart-lung transplant recipients 204
 risks 13, 14
- coronary artery bypass grafting 175, 177
- coronary dissection 77, 78, 174, 175
 progesterone and 175
- coronary heart disease 37–38, 174–177
 acute *see* myocardial infarction
 interventions in pregnancy 76–78, 175–177
 practical practice points 174
 previous myocardial infarction 177
 risk factors and prevalence 174
- coronary stenting 176
- corticosteroids *see* steroids
- cough, “high left atrial pressure”, mitral stenosis 126
- counseling
 antenatal 32, 43
 on contraception 6–7
 after fetal CHD diagnosis 89
 maternal arrhythmias 187
 post exposure to cardiac drugs 54
 preconception *see* preconception counseling
- C-reactive protein (CRP) 163, 165
- crown-rump length (CRL) 85
- cultural issues, preconception counseling 2
- cytomegalovirus (CMV) infection 202
- cytosporine 204
- cystic fibrosis 145, 199
- cystic medial necrosis 236
- cytomegalovirus (CMV) infection 202
- dalteparin 111
- deep vein thrombosis (DVT) 12, 221
- defibrillation 215
- delivery
 after death of mother 78

- after myocardial infarction 177
 antibiotic prophylaxis of
 endocarditis 193–194, 196
 aortic stenosis 130
 aortopathies 119–120
 cardiovascular changes 148
 care plan 210
 early *see* preterm delivery
 equipment 216
 fetal monitoring 210
 Fontan-type operations 139–140
 heart-lung transplant recipients
 205–206
 instrumental 210
 location for 90–91, 216
 maternal arrhythmias 187–188
 maternal CHD 216
 mode 209–210
 fetal CHD 91
 pulmonary hypertension
 156–157
 monitoring, pulmonary
 hypertension 155–156
 planning for 61, 208
 position for 210, 219
 postpartum period monitoring
 155–156
 right heart lesions 132, 140
 tertiary center 209
 timing 209
 fetal CHD 90–91
 pulmonary hypertension 155
 vaginal 131–141, 210
 dental hygiene 196
 dental treatment 4, 194
 depot medroxyprogesterone acetate
 (DMPA) 12, 13
 depression 206
 desogestrel 12–13, 16
 diabetes mellitus, heart transplant
 recipients 202
 diastolic function, in pregnancy 25, 48
 DiGeorge syndrome 4, 134–135,
 140
 digoxin 59, 186
 dilated cardiomyopathy (DCM) 160,
 161–162
 clinical features 161
 definition and etiology 161, 163, 167
 diagnosis 161
 long-term outcome 230
 PPCM and 161, 163, 165, 166–167
 pregnancy management 162
 pregnancy outcome 161–162
 prognosis 166–167
 diltiazem 58
 dinoprostone 61
 direct current (DC) cardioversion 58,
 180, 184, 213
 diuretics 54–55, 176
 Doppler echocardiography, in
 puerperium 224
 Doppler ultrasound velocimetry,
 umbilical artery 96, 101
 drug(s)
 cardiac, in pregnancy *see*
 cardiac drugs
 interactions 15, 61
 in puerperium, cardiovascular
 effects 220
 used in pregnancy, effect on cardiac
 disease 60–62
 drug abuse, endocarditis risk 192, 193
 ductus venosus blood flow, CHD
 screening 100
 Duke criteria, modified 196
 dyspnea 126, 146
 Ebstein anomaly of tricuspid valve
 135, 186
 chest X-ray 135
 echocardiography
 aortic stenosis 128
 aortopathies 118
 exercise/stress 49, 128
 fetal 33–34
 fetal screening for CHD 84, 86,
 87, 100
 counseling after 89
 equipment for and
 methods 88–89
 procedure 87, 89
 safety and guidelines 89
 see also congenital heart
 disease (CHD)
 frequency 47–48
 maternal, assessments made
 43, 47–48
 aortic dimensions 50
 cardiac pressures 50
 valvar abnormalities/
 function 49–50
 ventricular size/function 48–49
 transesophageal 70, 119, 213,
 214–215
 Ehlers–Danlos syndrome, type IV
 (vascular) 75, 76, 122, 237
 Eisenmenger syndrome 19, 33, 98, 148
 morbidity in puerperium 222
 mortality 149, 221
 oxytocic drug effects 149
 postpartum monitoring 47
 electrocardiography (ECG) 50
 fetal 91, 93
 maternal 126, 154
 electronic medical records 46
 embryopathy, warfarin (coumarin) 60
 emergency contraception 6, 8, 14
 endocarditis, infective 191–197
 acute/subacute 191
 antibiotic prophylaxis 75, 191,
 193–194, 196
 antibiotic treatment 191, 196, 197
 cardiac conditions at risk 192, 193
 definition 191
 diagnosis 192, 196
 epidemiology 191
 fetal mortality 193
 incidence in pregnancy 193, 194
 infecting organisms 191, 192, 193
 literature reviews 193, 194
 in maternal CHD 192, 193
 maternal mortality 193, 195
 pathogenesis 191–192
 practical practice points 191
 predisposing factors 191, 192–193,
 194, 196
 preventive measures 193–194, 196
 risk assessment 31
 surgical therapy 75, 197
 endomyocardial biopsy, peripartum
 cardiomyopathy 163
 endothelin-receptor antagonists 58,
 147, 152, 155
 endothelium, endocarditis
 pathogenesis 191–192
 enoxaparin 111
 epidural analgesia 25, 212
 heart-lung transplant
 recipients 206
 pulmonary hypertension 157
 equipment
 fetal CHD diagnosis 88–89
 labor and delivery 215–216
 ergometrine xi, 61, 211, 220
 ESSURE 11
 estimated date of delivery (EDD) 85
 ethacrynic acid 55
 European Society of Cardiology
 (ESC) 32, 36, 38–39, 44,
 117–118, 192
 exercise stress testing 2, 49, 50–51, 128
 extracorporeal membrane
 oxygenation 79
 extrasystoles (maternal) 180
 FDA drug categories 203
 female sterilization 11
 fertility 98, 204
 fetal anomalies, extracardiac, CHD
 risk 88
 fetal arterial blood flow
 redistribution 102
 fetal cardiac defects *see* congenital
 heart disease (CHD)
 fetal growth restriction (FGR) 7,
 33, 101
 beta-blocker use in pregnancy 59
 CHD and 90, 101–102
 risk, preconception counseling 3

Index

- fetal loss/fetal mortality 66, 75
 cardiopulmonary bypass 66
 Fontan repairs and 98
 risk, preconception counseling 3
- fetal organogenesis 53–54
- fetal venous Doppler 102
- fetal well-being, CHD 90, 96, 101–102
- fetus
 monitoring, vaginal delivery 210
 risks, preconception counseling 3, 7
 risks to in maternal cardiac disease 33
 surveillance, antenatal care 33–34
- first trimester screening, fetal CHD 92, 100
- flecainide 57, 185
- fluid retention 177
- folic acid 87
- Fontan circulation/-type operations 49, 98–99, 138–140, 222
 anticoagulation 139, 140
 complications after 3, 138–139
 delivery 139–140
 fetal/maternal outcome 98–99
 monitoring in pregnancy 139
 morbidity in puerperium 222
 prepregnancy evaluation/counseling 139
 right heart lesions as 133
- furosemide 55
- general anesthesia *see* anesthesia
- genetics referral 4
- gestational age, assessment 85
- glomerular filtration rate 21, 53
- glycoprotein IIb/IIIa (2b3a) inhibitors 77, 176
- guidelines
 antibiotic prophylaxis in endocarditis 194
 cesarean section 210
 delivery mode 209
 endocarditis diagnosis 192
 immunosuppressive drugs 203
 pregnancy management in cardiac disease 36, 44
 pregnancy management in Marfan syndrome 117–118
 pregnancy management in transplant recipients 204–205
- heart, anatomical changes in pregnancy 22–23, 25, 30
- heart disease *see* cardiac disease (maternal)
- heart-lung transplantation 201
- heart murmurs, systolic 120
- heart rate
 fetal, maternal cardiac surgery effect 103
- peridelivery 25
- postpartum 26
- pregnancy 20, 21–22, 174, 181, 201
- heart transplantation 165, 199–206
 arrhythmias 201
 breastfeeding 206
 depression 206
 epidemiology 199, 200
 fertility, counseling and contraception 204
 fetal complications 203–204
 immunosuppressive drugs 202, 203
 maternal complications 202–203, 223
 maternal mortality 203
 morbidity in puerperium 223
 obstetrical care 204–206
 physiology in pregnancy 201–202
 practical practice points 199
 rejection 202–203
 risks of pregnancy 200–204
 surveillance during pregnancy 204–205
- heart valves, prosthetic *see* prosthetic heart valves
 “Heart Valve Teams” 197
- hematocrit, maternal 97, 103
- hemodynamic changes
 in labor/peridelivery 25–26, 200, 218–219
 in pregnancy 19–22, 30, 47, 67, 115, 148, 174, 200–201, 218
 abnormal cardiac anatomy 235
 arrhythmia mechanisms 181
 AV valve regurgitation 235
 heart transplant 201, 202
 longitudinal studies 20
 in puerperium 218–219
 pulmonary hypertension 148, 154
- hemoglobin levels, maternal 97, 98
- hemostatic changes, puerperium 220
- heparin 4, 59–60, 67, 68, 107
 low molecular weight *see* low-molecular-weight heparin (LMWH)
 unfractionated, prosthetic valves 107–109, 112
- high-risk group (WHO III/II–III)
 conditions 46, 208
 preconception counseling 1, 7, 8
- hormonal changes in pregnancy 76
- “hub and spoke” model of care 41, 42
- hydralazine 55–56
- hydrops 92
- hypercoagulable state 30, 175, 176
- hyperkalemia 67, 68
- hypertension
 coarctation of aorta 120–121
 heart transplant recipients 202
- peripartum cardiomyopathy and 163
 in pregnancy 121
 in puerperium 220
- hypertrophic cardiomyopathy (HCM) 99, 160, 169–170
 definition and etiology 169
 diagnosis and clinical features 169
 management 169–170
 outcome, and mortality 169
- hypoplastic left heart syndrome 85, 92
- hypotension, maternal 67, 103, 213
- hypothermia, cardiopulmonary bypass 66, 67–68
- hypoxemia 102
- hypoxia, fetal 7, 102
- hysteroscopy, ESSURE sterilization 11
- iloprost 151, 155
- IMAC-2 study 167
- immunoglobulins, PPCM etiology 163
- immunosuppression, maternal 202
- immunosuppressive therapy, transplant recipients 202, 203
- impedance cardiography 219
- implantable cardioverter-defibrillator 79, 167, 184
- induction of labor xi
- infections 163, 202
- infectious endocarditis *see* endocarditis
- inferior vena cava filter 79
- inflammation 163, 191–192
- information, for mother, from obstetrician 32
- informed choice, preconception counseling 2–3
- Inoue balloon 73
- international registries 209
- intra-aortic balloon pumping 68, 79
- intra-atrial re-entrant tachycardia (IART) 183
- intracardiac shunt 150, 221
- intrapartum care xi, 25–26, 61
- intrauterine coils 152
- intrauterine death, fetal CHD 90
- intrauterine devices *see* copper intrauterine device (Cu-IUD)
- intravenous fluids, puerperium 220
- intraventricular conduction block 185
- intubation, failed 211, 213
- ionizing radiation *see* radiation
- ischemic heart disease *see* coronary heart disease
- “jet” lesion 192
- Khairy study 44, 45
- kidney transplant recipients 199

- labor
 aortic stenosis 130
 cardiac output *see* cardiac output (CO)
 cardiovascular changes 25–26, 148
 care plan 210
 hemodynamic changes 218–219
 induction 209
 location 215
 right heart lesions 132
 second stage, cardiac output 209
 third stage 209, 210–211
- lactation *see* breastfeeding
- laparoscopic female sterilization 11
- left atrial pressure 50, 169
- left atrium, enlargement in pregnancy 22
- left to right shunting 133, 134
- left ventricle
 anatomical changes in pregnancy 23, 24, 25, 48, 218
 anatomical changes in puerperium 219
 functional changes after delivery 219
 functional changes in pregnancy 23–25, 48–49, 218
 impaired function 37–38, 48
- left ventricular assist device (LVAD) 79
- left ventricular dilatation 161
- left ventricular ejection fraction (LVEF) 22, 48
 dilated cardiomyopathy 160, 161, 162
 PPCM 160, 162, 166, 167
 recurrence and risk 167–168
 previous myocardial infarction 177
- left ventricular end-diastolic diameter (LVEDD) 23, 24, 166, 219
- left ventricular failure 164
- left ventricular non-compaction cardiomyopathy (LVNC) 160, 170
- left ventricular outflow tract obstruction 49, 97, 169
- levonorgestrel emergency contraception 14
- levonorgestrel intrauterine system (LNG-IUS, Mirena®) 6, 13
- lidocaine 57, 185
- Lithium Dilution Cardiac Output Monitoring (LiDCO) 155, 156
- liver transplant recipients 199
- Loeys-Dietz syndrome 118, 237
- long QT syndrome 99, 181, 223
- long-term outcome, pregnancy on heart disease 45, 227–232, 234–237
 need for information on 227–228
- practical practice points 227
see also specific conditions
- loop diuretics 55
- “low cardiac output status” 138
- low-dose aspirin 60, 78, 106, 134
 acute coronary syndrome 176
 prosthetic heart valves and 111–112
- low-molecular-weight heparin (LMWH) 60
 acute coronary syndrome 176
 advantages 110
 adverse effects and thrombosis 110–111
 peripartum cardiomyopathy 165
 prosthetic heart valves 110–111, 112
 strategy for use 111
 withdrawal before delivery 111
- in puerperium 224
- low-risk group (WHO I/II) conditions 45, 208–209
- lung transplantation 199–206
 breastfeeding 206
 complications (maternal/fetal) 202–204
 epidemiology 199–200, 201
 fertility, counseling and contraception 204
 immunosuppressive drugs 202, 203
 obstetrical care 204–206
 rejection 202–203
 surveillance during pregnancy 204–205
- magnetic resonance imaging (MRI)
see cardiac MRI
- magnetocardiography 91
- male sterilization 11
- mannitol 55
- Marfan syndrome 4–5, 37, 99, 115, 116–118, 236
 aortic dissection 75, 76, 117, 236
 symptoms 119
 treatment 119
- aortic root 115, 117, 231–232, 236
- chest X-ray 119
- contraception 16
- CT angiogram 118
- genetics, prevalence and pregnancies 116
- long-term outcome after pregnancy 117, 231–232, 236–237
- management guidelines 117–118
- medical therapy 118
- non-aortopathy complications 116, 117
- postpartum care 47
- pregnancy as risk factor for aortic disease 117
- recurrence risk 118
- risk stratification 117–118
- “maternal cardiac center” 31
- maternal monitoring, peripartum 214–215, 216
 basic non-invasive 214
 invasive 214
 non-invasive cardiac output 214–215
- maternal monitoring, puerperium 218
 cardiovascular 224
 invasive 224
 non-invasive 224
- maternal morbidity 29–30, 140
 risk, pregnancy in cardiac conditions 7–8
- maternal mortality 1, 6, 29–30
 cardiac causes 2, 6, 126, 208
 risk in pregnancy 7–8, 29–30, 36, 96
 timing during puerperium 221–222
see also specific conditions
- mean pulmonary artery pressure (MPAP) 144
- medical history 47
- medical records 33, 46–47
- metabolic risk factors, fetal cardiology referral 87
- microarray CGH 89
- microchimerism, fetal 163–164
- mifepristone 15
- Mirena® (levonorgestrel intrauterine system) 6, 13
- miscarriage *see* fetal loss/fetal mortality
- mortality
- misoprostol xi, 61, 211
- mitral valve
 balloon dilatation 72, 126–127
 echocardiography 49
 Marfan syndrome 236
 parachute 127
 regurgitation 49, 74–75, 116
 replacement 72
 emergency 127
 risks (fetal/maternal) 127
- mitral valve stenosis 22, 33, 49, 125–127
- congenital 127
- delivery mode, and complications 127
- history and examination 126
- investigations 126
- long-term outcome after pregnancy 228
- maternal complications 71, 99, 127
- pathophysiology 125–126
- poor outcome, risk factors 127
- practical practice points 125
- rheumatic 125–126, 228
- severity 126
- signs/symptoms 125, 126

Index

- mitral valve stenosis (*cont.*)
 therapeutic interventions 71–73, 99, 126–127
 balloon inflation 72, 126–127
 surgical approach, outcome 72, 102–103
see also percutaneous balloon mitral valvuloplasty (PBMV)
- mitral valvotomy 127
 balloon 72, 126–127
 closed 68, 72, 127
- mitral valvuloplasty
 open 72
 percutaneous balloon *see* percutaneous balloon mitral valvuloplasty (PBMV)
- morphine 176
- multidisciplinary team (MDT) 41
 antenatal care 33, 38–39, 46
 heart-lung transplant recipients 204
 maternal arrhythmias 188
 peripartum care 208, 215
 planning puerperium management 223
 postpartum surveillance 67
 puerperium, care in 223–225
 referral, antenatal care 36, 73
- multiple aortopulmonary collateral arteries (MAPCAs) 133, 140
- multiple pregnancy, precautions/avoiding 4
- mycophenolate mofetil (MMF) 203
- myocardial infarction 76, 77, 78
 acute, in pregnancy 174
 management 77, 175–177
 acute, in puerperium 221
 coronary dissection and 175, 221
 delivery after 177
 diagnosis, differential diagnosis 175
 mortality 76, 78, 175, 222
 predictors and risk factors 76–77, 78, 174
 previous
 advice before conception 177
 pregnancy management 177
 recurrence risk reduction 176
 resuscitation 78
- myocardial ischemia 77, 78, 221
- National Institute for Health and Care Excellence (NICE) 85–86, 194
- National Transplantation Pregnancy Registry (NTPR) 199, 200, 201, 203
- neonates
 cardiac drug effects 55, 59
 complication risk factors 44, 46
 neurodevelopmental impairment, fetal CHD 90
- New York Heart Association (NYHA), cardiac function classification 32, 44, 97
- Nexplanon® contraceptive implant 12, 13–14
- NHS fetal anomaly screening program (NHS FASP) 85–86
- nitrates 58, 176
- nitric oxide 19, 213
- nitrous oxide 214
- Noonan syndrome 136
- norethisterone enanthate (NET-EN) 13
- NT-proBNP (N-terminal prohormone brain natriuretic peptide) 161, 222
- nuchal skinfold thickness 84
- nuchal translucency 33, 99–100
 CHD risk 85, 88, 99–100
- nuclear imaging 51
- obstetric complications 39
- obstetrician, perspective on antenatal care 29–34
 cardiac condition diagnosis 30–31
 fetal surveillance 33–34
 frequency of visits 34
 information for mother 32
 location of care 31
 multidisciplinary team and 33
 planning care 32–33
 postnatal care 34
 practical practice points 29
 risk assessment *see* risk assessment
- obstetric issues 209–211
- obstetric unit, local, CHD screening 85–86
- opioids 213, 214, 224
- orthopnea 126
- outcomes, long-term *see* long-term outcome
- oxidative stress 164
- oxygen
 during general anesthesia 213
 in puerperium 224–225
- oxygen saturation, arterial, maternal 98, 148
 prepregnancy, live births and 7
- oxytocic drugs, in pulmonary hypertension 149, 156
- oxytocin xi, 60–61, 209, 210, 212
 cardiovascular changes 211
 effect in cardiac disease 60–61
 peripartum cardiomyopathy 164
- pacemaker insertion 79, 102, 185
- pacing, temporary 102
- pain relief *see* analgesia
- paradoxical emboli 12, 78, 134
- paroxysmal supraventricular tachycardia (PSVT) 183
 incidence 180, 183
 management 183
- patent foramen ovale (PFO) 12
- percutaneous balloon aortic valvuloplasty (PBAV) 74
- percutaneous balloon mitral valvuloplasty (PBMV) 68, 71, 72
 contraindications 73
 Inoue balloon method 73
 radiation risks 72–73
- percutaneous coronary intervention (PCI) 65–79, 174, 175
 fetal risks 175
 as first choice in pregnancy 176
- perineal injury, antibiotic prophylaxis 194
- periodontal disease 192
- peripartum cardiomyopathy (PPCM) 48, 160, 162–169
 breastfeeding 165
 bromocriptine effect 164, 165, 222
 clinical features, severity 164–165
 definition 162, 222
 diagnosis 165
 dilated cardiomyopathy and 161, 163, 165, 166–167
 familial clustering 163
 incidence 162
 long-term outcome 230, 235–236
 LV recovery 38, 166, 168
 management 165–166
 morbidity in puerperium 222
 mortality and prognosis 166–167, 168, 236
 pathophysiology/etiology 160, 163–164
 prognostic factors 166, 167
 recurrence, risk in future pregnancy 3, 167–169, 236
 risk factors 163
- peripartum period, management 208–216
 anesthesia *see* anesthesia
 cardiac disease significance 208–209
 monitoring *see* maternal monitoring, peripartum
 obstetric issues 209–211
 planning for delivery 208
 practical practice points 208
 resources 215–216
 equipment and environment 215–216
 staff 215
 training and resuscitation 215
see also delivery *see also* labor
 peripheral vasodilatation 19

- pharmacokinetics 53, 203
 phenytoin 57
 polymerase chain reaction (PCR) 89
 postpartum care 34, 67, 216
 cardiovascular changes 26
 monitoring 47
 specific cardiac conditions 47,
 132, 188
 postpartum hemorrhage 210, 211,
 218, 220
 in aortopathies 119
 prevention/reduction 211
 posture
 peridelivery 25, 210, 219
 in pregnancy 22
 in puerperium 224–225
 preconception counseling 6–7, 43, 73
 arrhythmias (maternal) 3, 187
 class 4 cardiac conditions 1, 7, 8
 components 1
 consensus statements 70, 73
 cultural background and diversity 2
 drug (cardiac) exposure 54
 Fontan-type operations 139
 heart-lung transplant recipients 204
 information provided 2
 on clinical management 3
 on contraception or
 termination 3
 language appropriateness 3
 informed choice 2–3
 practical practice points 1
 pregnancy preparation 3–4
 prenatal tests 4
 previous myocardial infarction 177
 pulmonary hypertension
 152–153, 154
 right heart lesions 131–132
 on risks 6–7, 29, 32
 to fetus 3, 7
 by medical condition
 classification 1, 7–8
 to mother 2–3, 7, 8
 preeclampsia 47, 163, 202, 220
 pregnancy preparation 3–4
 pregnancy timing 4
 preterm delivery 39, 99, 209
 risks/rates 3, 33
 procainamide 185
 progesterone 175
 progestogen-only
 contraceptives 12–14
 advisability, for different conditions/
 states 10, 152
 injectable 13
 problems 12
 progestogen-only pills 12–13
 safety/advantages 12
 subdermal implants (Nexplanon®)
 6, 13–14, 16
 prolactin, PPCM and 164, 165, 222
 propafenone 185
 prostacyclin 58
 prostaglandin E2 209
 prostaglandin F2a (carboprost) 61,
 211
 prostaglandins, effect in cardiac
 disease 61
 prosthetic heart valves 75, 106–112
 anticoagulation strategies 106, 107
 aspirin 111–112
 comparisons, adverse effects
 108–109
 fetal complications/loss 108–109
 intravenous unfractionated
 heparin 108, 109
 LMWH 110–111, 112
 maternal complications 108,
 109
 risk stratification and warfarin
 use 110
 subcutaneous unfractionated
 heparin 108
 unfractionated heparin
 107–109, 112
 warfarin 108–110, 112
 interventions 75
 mechanical 106, 107, 112
 puerperium 223
 practical practice points 106
 thrombosis 75, 107, 110, 111
 thrombolysis in 75
 tissue (bioprostheses) 106–107, 112
 degeneration 106–107, 237
 long-term outcome 231, 237
 puerperium 223
 replacement (repeat) 106–107
 puerperium, management 218–225
 aortopathies 119
 cardiovascular monitoring 224
 hemostatic changes 220
 morbidity in cardiac disease
 222–223
 multidisciplinary care 223–225
 pain relief, oxygen and posture
 224–225
 pharmacological 224
 physiological changes 218–220
 circulating volume changes
 219–220
 drugs and fluids, effects 220
 hemodynamic changes 218–219
 practical practice points 218
 risks in women with cardiac disease
 220–221, 223
 in significant cardiac disease
 223–225
 thromboprophylaxis 224
 timing of maternal deaths 221–222
 pulmonary arterial hypertension 145
 pulmonary arterial vasodilators
 145, 146
 pulmonary artery catheterization
 214, 215
 pulmonary atresia with VSD 140
 fetal complications 140
 maternal complications 140
 pulmonary blood supply 140
 surgical repair 140
 pulmonary blood flow, normal
 pregnancy 30
 pulmonary capillary wedge pressure
 (PCWP) 218, 220
 pulmonary hypertension (PH) 2,
 144–157
 classification 145
 clinical features 146
 contraception 15–16, 152
 definition 144
 delivery
 cardiovascular system 148, 156
 mode and anesthesia
 156–157, 213
 monitoring at 155–156
 timing 155
 diagnosis and investigations
 146–147
 epidemiology 147
 idiopathic 145, 147, 148, 149, 154
 management, PAH treatment
 era 152
 long-term outcome 228–229
 management in/of pregnancy
 147–148
 consensus statement 148, 152
 PAH treatment era 150–152, 155
 pragmatic approach 152, 153
 pre-PAH treatment era 148–150
 morbidity in puerperium 222
 mortality 15, 50, 97, 144, 147,
 148, 153
 PAH treatment era 150–151, 228
 postpartum 150, 151, 221, 228
 pre-PAH treatment era 149–150
 risk factors 149
 oxytocic drugs effects 149, 156
 pathophysiology 21, 50, 145–146
 postpartum period 148
 monitoring 47, 155–156
 practical practice points 144
 preconception counseling
 152–153, 154
 pregnancy 153, 157
 assessment and follow-up 155
 cardiovascular adaptations 148
 hemodynamic changes 148, 154
 risks of 15, 50, 58, 97, 144, 146,
 152, 228
 pulmonary artery pressure 50,
 144, 146

Index

- pulmonary hypertension (PH) (*cont.*)
 severity, pregnancy continuation 228
 survival 147, 153
 treatment 147, 155
 medical 58, 147
 UK specialist centers 147, 152
- pulmonary hypertensive crisis 213
- pulmonary edema 164, 220
- pulmonary pressure, estimation 50
- pulmonary regurgitation 134
- pulmonary valve stenosis 74, 135–136
 fetal 92
- pulmonary vaso-occlusive disease (PVOD) 146
- pulmonary venous hypertension 146
- pulsatility index (PI), umbilical artery 102
- pulse oximetry 214
- QRS prolongation 185
- quinidine 57
- radiation
 avoidance and alternatives 70, 71
 cancer and hereditary effects risk 70
 effective dose 69
 fetal and maternal risks 69–71
 fetal dose, risks 70, 71, 175, 176
 from X-rays 175
 fetal sensitive period 175, 176
 high-dose exposure, damage 70
 key points regarding 71
 measurement parameters 69–70
 percutaneous balloon mitral valvuloplasty 72–73
 shielding of pelvis/abdomen 70–71, 175
- recombinant tissue plasminogen activator (rtPA) 175–176
- records, antenatal care 33, 46–47
- relaxin 19
- report, antenatal care 40–41
- resources, peripartum period
see peripartum period, management
- respiratory depression, neonatal 213
- restrictive cardiomyopathy 160, 170
- resuscitation 215
- reversed end-diastolic flow (RED) 101–102
- rheumatic heart disease 125–126
- right heart failure 146
- right heart lesions (maternal) 132–140
 antenatal care 132
 antibiotic prophylaxis 132
 labor and delivery 132
 maternal/fetal outcome 140, 141
 postpartum period 132
 practical practice points 131
- preconception evaluation/
 counseling 131–132
- pressure overload, conditions 133
- volume overload, conditions 132, 141
see also individual conditions
- right ventricle
 anatomical changes in pregnancy 23
 assessment in pregnancy 49
 pressure overload, conditions causing 133
- pulmonary hypertension,
 outcome 229
- systemic, long-term outcome 235
- tetralogy of Fallot, outcome 229–230, 235
- volume overload, lesions causing 132, 141
- right ventricular assist device (RVAD) 79
- right ventricular outflow obstruction 50, 134, 135
 congenital, pulmonary stenosis 135, 136
- risk assessment 38, 40
 in antenatal care 31–32, 44–45, 227
 additional risk factors 32
 cardiac lesions 31, 44
 cardiovascular event predictors 44, 45
 moderate-/severe-risk lesions 31–32, 208
 modified WHO classification 44, 45, 46
 NYHA classification 32, 44, 97
 trivial/low-risk cardiac lesions 31, 208–209
 neonatal complications 44, 46
 peripartum period 208
 preconception counseling 2–3, 7
 scoring systems 2, 44, 45
- ritodrine 61–62
- Ross procedure 231
- Royal College of Obstetricians and Gynaecologists (RCOG) 31, 36
- salpingectomy, bilateral 11
- scoring systems, risk assessment 2, 44, 45
- sepsis/septicemia 194, 221
 “seriously handicapped”, definition, pregnancy termination 90
- Shone syndrome 127
- sick sinus syndrome 182, 187
- sildenafil 58
- sinus nodal re-entry tachycardia (SNRT) 183
- sinus node dysfunction 185
- sotalol 57–58, 185
- spinal block 212
- spironolactone 55
- staff 215
- STAT3, deletion, in PPCM 164
- sterilization 11
- steroids 92, 209
 transplant recipients 203, 205
- streptokinase 175–176
- stroke volume
 normal pregnancy 20, 22
 postpartum 25, 26
 puerperium 219
- sudden cardiac death (SCD) 37, 90
- supraventricular arrhythmias 79
- supraventricular tachycardia (SVT) 183
 in CHD 182
 fetal 91
 incidence 182, 183
 management in pregnancy 182
 mechanism in CHD 181
 paroxysmal *see* paroxysmal supraventricular tachycardia (PSVT)
- surgical interventions *see* cardiac surgical interventions
- sympathetic tone, during cesarean section 213
- syncope 146
- Syntocinon® 164, 220
- “systemic right ventricle” 229, 235
- systemic sclerosis 147
- systemic vascular resistance, drop 19, 20, 21, 30
- systolic function, in pregnancy 23–25, 48
- systolic pulmonary artery pressure (SPAP) 146
- tachyarrhythmias 182–184
see also specific arrhythmias
- tachycardia
 fetal, management 91–92
 sinus, in pregnancy 22
- Takayasu arteritis 122
- “tariff system” 34
- Teichholz formula 23
- teratogenic drugs 3, 4, 53–54
 antiarrhythmic drugs 182
 exposure, referral for fetal cardiology 87
 FDA categories 203
 immunosuppressive drugs 203
see also cardiac drugs
see also specific drugs
- teratogenicity, contrast agents 71
- termination of pregnancy 6, 15
 counseling on 32
 fetal CHD 90, 100
 information on 3
 legal limit 90

- medical 15, 90
 surgical 15
 tertiary unit 36, 209
 facilities 38
 tetralogy of Fallot 4, 78, 134–135, 140
 arrhythmias 186
 corrected 134
 fetal/maternal outcome 98,
 134, 135
 morbidity in puerperium 222
 lesions/defects 134, 135
 pregnancy long-term impact on
 134, 228, 229–230, 235
 thiazide diuretics 54–55
 thromboembolism
 puerperium 30, 220, 221
 risks, preconception counseling 3
 risks in pregnancy 30, 175
 transposition of great arteries 138
 thrombolysis 175–176
 complications in pregnancy 176
 myocardial infarction 77, 174,
 175–176
 prosthetic valve thrombosis 75
 thrombophilia 77, 79
 thromboprophylaxis 36, 165
 in puerperium 224
 thrombus, endocarditis pathogenesis
 191–192
 ticagrelor 176
 tissue Doppler imaging (TDI) 25
 tocolytic agents 67
 total cavopulmonary connection
 (TCPC) 138
 training 215
 transcatheter interventions, fetal 92
 transesophageal echocardiography
 (TOE) 70, 119, 213, 214–215
 transposition of the great arteries
 (TGA) 84–85, 137–138
 arrhythmias 187
 atrial switch operation 137, 187, 235
 congenitally corrected 136–137, 187
 long-term outcome 229, 235
 monitoring during pregnancy
 137–138
 prepregnancy evaluation 137
 transthoracic echocardiography (TTE)
 126, 146, 165
 tricuspid regurgitation 100
 tricuspid valve, Ebstein anomaly
 see Ebstein anomaly of
 tricuspid valve
 trisomy, screening 85, 89
 tubal ligation 11
 Turner syndrome 122, 237

 UK Medical Eligibility Criteria
 (UKMEC) 6, 7, 10
 Ulipristal acetate (UPA) 14
 ultrasound, fetal 84, 85
 3D and 4D, fetal heart screening 93
 see also echocardiography
 umbilical artery
 Doppler ultrasound velocimetry
 96, 101
 pulsatility index 102
 univentricular heart 133, 138–140, 187
 peripartum period 208–209
 pregnancy long-term impact on 228
 see also Fontan circulation/
 -type operations
 uterine artery Doppler screening
 96, 101
 uterine blood flow 67, 101
 high impedance, persistence 101
 uterine contractions 67, 148
 uterine hemorrhage 122
 uterine hyperstimulation 209
 uteroplacental blood flow 103

 vaginal delivery, cesarean section *vs* 61
 valve thrombosis 50
 valvotomy/valve repair, before
 pregnancy 3
 valvular heart disease
 echocardiography 49–50
 fetal/maternal outcome 99
 long-term outcome 228, 230–231
 morbidity in puerperium 222–223
 surgical intervention 71–75
 vascular endothelial growth factor
 (VEGF) 164
 vasodilatation, peripheral 19, 74,
 212, 220
 vasodilators 145, 146, 162
 vasovagal episodes, pulmonary
 hypertension 15
 venous thrombosis 11
 ventricular dysfunction 235
 ventricular ischemia 221
 ventricular septal defect (VSD) 192
 pulmonary atresia with *see*
 pulmonary atresia with VSD
 tetralogy of Fallot 134, 135, 140
 ventricular tachycardia (VT) 182–183
 in CHD 181, 182
 incidence 180, 182
 management in pregnancy 182–183
 verapamil 58
 virus infections 163, 202
 vitamin K antagonists 60
 volume overload 132, 141, 181

 warfarin 4, 53, 110
 combined hormonal
 contraception and 12
 embryopathy 60, 108, 109–110
 dose-dependent relationship 110
 in pregnancy 32, 60, 108–109
 discontinuation for delivery 110
 prosthetic heart valves
 108–110, 112
 warm heart surgery 68
 Wolf–Parkinson–White syndrome
 135, 180–181
 World Health Organization (WHO)
 contraceptive classification 6, 7
 heart disease risk classification 38,
 44, 45, 46

 ZAHARA study 44, 45